- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06094894
Effects of Sucralose in Gut Intestinal Microbiota and Postprandial GLP-1
Changes in Gut Microbiota and Postprandial GLP-1 Concentration Due to Sucralose Consumption
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study design:
This is a triple-blind, parallel, placebo-controlled, randomized clinical trial.
Sample size:
The sample size was calculated to observe a difference of 25% in GLP-1 area under the curve.
The calculation was done considering a probability of type I error (α) of 5%, with a power of 80% and adding an extra 20% for potential losses at follow-up.
The estimated sample size for the study is 40 subjects, 20 per group.
Randomization:
The participants will be randomly assigned to one of the two groups (sucralose or placebo) using the website Randomization.com (http://www.randomization.com) with a balanced block design of 5 blocks with 8 subjects each. The random allocation sequence will be done by an external researcher.
Intervention:
The intervention will consist of capsules filled with pure sucralose or placebo (cornstarch) accordingly to the group assignment. Each capsule will contain 90 mg of sucralose or placebo. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of sucralose or placebo, this quantity corresponds approximately to the 30% of the acceptable daily intake (ADI) of sucralose for a lean person. This was calculated based on the ADI established by the joint Food and Agriculture Organization of the United Nations (FAO)/World Health Organization (WHO) expert committee on food additives (JECFA) of 15 mg per kg of body weight per day of sucralose.
The use of identical capsules will allow the blinding, the capsules will be deposited in bottles numbered sequentially according to the enrollment process and neither the participants nor the researches will know the content of the capsules or the group assigned.
Visit 1
An oral glucose tolerance test (OGTT) will be performed to confirm that participants do not have diabetes or prediabetes. Fasting insulin, lipid profile and glycated hemoglobin will be measured. Also, anthropometry (weight, height, waist, and hip circumference), blood pressure and heart rate will be documented. Body composition will be evaluated with dual X-ray absorptiometry (DXA) already available in the Research Unit and bioelectrical impedance. Physical activity will be registered with the questionnaire from the University of Laval that measure energy expenditure in Kcal per day. A format for three-day food intake record will be given to be prospectively registered by participants.
Visit 2
The three-day food record will be requested and reviewed to evaluate food consumption habits. A mixed meal tolerance test will be performed over two hours. The meal will consist of 523 kcal (49% carbohydrates, 17% protein, 34% lipids). Blood samples will be collected at 0, 30, 60, 90 and 120 minutes to measure glucose, insulin and glucagon-like peptide type 1 (GLP-1) concentrations. Also, lipopolysaccharide (LPS), C-reactive protein (CRP), interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNF-α) concentrations will be measured at the basal time. Ten minutes before the test participants will consume a capsule containing either sucralose or placebo (120 mg).
Participants will proportionate the first stool sample to evaluate gut microbiota.
The researchers will proportionate the bottle with capsules that each participant will consume during the intervention period (30 ± 2 days) in this visit. Also, each participant will be asked to record on the adherence format if they consumed the capsule at breakfast, lunch, and dinner each day of the intervention period and to record any symptom related to capsules ingestion. Another format to record three-day food consumption again will be given.
Visit 3
Participants will proportionate the second stool sample to evaluate changes in gut microbiota. Also, the physical activity questionnaire will be applied again, and the second 3-day food record will be obtained to evaluate changes in physical activity and food habits, respectively. The second mixed meal tolerance test will be performed following the same procedures as visit 2. Participants will be asked to return the empty bottles to quantify adherence to the intervention. In addition, adherence and symptoms formats will be collected.
Visit 4
Participants will be asked to assist one month after visit 3 to make a final evaluation of fasting glucose, insulin, and lipid profile concentrations. The physical activity questionnaire will be applied again, and a third 3-day food record will be collected to evaluate changes in physical activity and food habits, respectively.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Paloma Almeda-Valdes, MD, PhD
- Phone Number: 2405 +525554870900
- Email: paloma.almedav@incmnsz.mx
Study Contact Backup
- Name: Alonso Romo-Romo, RD, PhD
- Phone Number: +525554870900
- Email: alonso.romor@incmnsz.mx
Study Locations
-
-
-
Mexico City, Mexico, 14080
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Normal BMI (18.5-24.9 kg/m2)
- Low habitual consumption of non-nutritive sweeteners (NNS
- Fasting plasma insulin concentration of <12 mU/L
Exclusion Criteria:
- Diabetes or altered glucose metabolism (abnormal fasting glucose, glucose intolerance or elevated glycated hemoglobin)
- Use of antibiotics in the last 3 months
- Use of probiotics through pharmaceutical products
- Liver or kidney disease
- Use of medications that could interfere with insulin sensitivity
- Severe intestinal diseases
- History of bariatric surgery
- Pregnancy or lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
The intervention will consist of capsules filled with placebo (cornstarch).
Each capsule will contain 90 mg of cornstarch.
Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of placebo, this quantity is in order to match the sucralose consumed in the intervention group.
|
Cornstarch without significant physiological effects
|
Experimental: Sucralose
The intervention will consist of capsules filled with pure sucralose.
Each capsule will contain 90 mg of sucralose.
Participants will be asked to consume one capsule in each meal (three per day) to achieve an ingestion of 270 mg of sucralose, this quantity corresponds approximately to the 30% of the acceptable daily intake (ADI) of sucralose for a lean person.
This was calculated based on the ADI established by the joint FAO/WHO expert committee on food additives (JECFA) of 15 mg per kg of body weight per day of sucralose.
|
Food additive used to replace sugar providing a sweet taste without calories.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GLP-1
Time Frame: baseline and 30 days after the intervention
|
To evaluate the changes in postprandial GLP-1 area under the curve during a mixed meal after sucralose consumption in comparison to placebo
|
baseline and 30 days after the intervention
|
gut microbiota
Time Frame: baseline and 30 days after the intervention
|
To compare the change in the relative abundance of colony forming units of bacterial genus and species after sucralose consumption in comparison to placebo through messenger RNA sequencing
|
baseline and 30 days after the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
C-peptide
Time Frame: baseline and 30 days after the intervention
|
To evaluate the changes in postprandial C-peptide concentrations during a mixed meal after sucralose consumption in comparison to placebo
|
baseline and 30 days after the intervention
|
C-reactive protein
Time Frame: baseline and 30 days after the intervention
|
To determine the effects of sucralose consumption in C-reactive protein concentrations in comparison to placebo
|
baseline and 30 days after the intervention
|
IL-6
Time Frame: baseline and 30 days after the intervention
|
To determine the effects of sucralose consumption in IL-6 concentrations in comparison to placebo
|
baseline and 30 days after the intervention
|
Tumor necrosis factor-alpha
Time Frame: baseline and 30 days after the intervention
|
To determine the effects of sucralose consumption in tumor necrosis factor-alpha concentrations in comparison to placebo
|
baseline and 30 days after the intervention
|
glucose
Time Frame: baseline and 30 days after the intervention
|
To evaluate the changes in postprandial glucose concentrations during a mixed meal after sucralose consumption in comparison to placebo
|
baseline and 30 days after the intervention
|
insulin
Time Frame: baseline and 30 days after the intervention
|
To evaluate the changes in postprandial insulin concentrations during a mixed meal after sucralose consumption in comparison to placebo
|
baseline and 30 days after the intervention
|
lipopolysaccharide
Time Frame: baseline and 30 days after the intervention
|
To determine the effects of sucralose consumption in lipopolysaccharide concentrations in comparison to placebo
|
baseline and 30 days after the intervention
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, Israeli D, Zmora N, Gilad S, Weinberger A, Kuperman Y, Harmelin A, Kolodkin-Gal I, Shapiro H, Halpern Z, Segal E, Elinav E. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014 Oct 9;514(7521):181-6. doi: 10.1038/nature13793. Epub 2014 Sep 17.
- Pepino MY, Tiemann CD, Patterson BW, Wice BM, Klein S. Sucralose affects glycemic and hormonal responses to an oral glucose load. Diabetes Care. 2013 Sep;36(9):2530-5. doi: 10.2337/dc12-2221. Epub 2013 Apr 30.
- Romo-Romo A, Aguilar-Salinas CA, Gomez-Diaz RA, Brito-Cordova GX, Gomez-Velasco DV, Lopez-Rocha MJ, Almeda-Valdes P. Non-Nutritive Sweeteners: Evidence on their Association with Metabolic Diseases and Potential Effects on Glucose Metabolism and Appetite. Rev Invest Clin. 2017 May-Jun;69(3):129-138. doi: 10.24875/ric.17002141.
- Romo-Romo A, Aguilar-Salinas CA, Brito-Cordova GX, Gomez-Diaz RA, Almeda-Valdes P. Sucralose decreases insulin sensitivity in healthy subjects: a randomized controlled trial. Am J Clin Nutr. 2018 Sep 1;108(3):485-491. doi: 10.1093/ajcn/nqy152.
- Lertrit A, Srimachai S, Saetung S, Chanprasertyothin S, Chailurkit LO, Areevut C, Katekao P, Ongphiphadhanakul B, Sriphrapradang C. Effects of sucralose on insulin and glucagon-like peptide-1 secretion in healthy subjects: a randomized, double-blind, placebo-controlled trial. Nutrition. 2018 Nov;55-56:125-130. doi: 10.1016/j.nut.2018.04.001. Epub 2018 Apr 21.
- Dalenberg JR, Patel BP, Denis R, Veldhuizen MG, Nakamura Y, Vinke PC, Luquet S, Small DM. Short-Term Consumption of Sucralose with, but Not without, Carbohydrate Impairs Neural and Metabolic Sensitivity to Sugar in Humans. Cell Metab. 2020 Mar 3;31(3):493-502.e7. doi: 10.1016/j.cmet.2020.01.014.
- Suez J, Cohen Y, Valdes-Mas R, Mor U, Dori-Bachash M, Federici S, Zmora N, Leshem A, Heinemann M, Linevsky R, Zur M, Ben-Zeev Brik R, Bukimer A, Eliyahu-Miller S, Metz A, Fischbein R, Sharov O, Malitsky S, Itkin M, Stettner N, Harmelin A, Shapiro H, Stein-Thoeringer CK, Segal E, Elinav E. Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance. Cell. 2022 Sep 1;185(18):3307-3328.e19. doi: 10.1016/j.cell.2022.07.016. Epub 2022 Aug 19.
- Bueno-Hernandez N, Esquivel-Velazquez M, Alcantara-Suarez R, Gomez-Arauz AY, Espinosa-Flores AJ, de Leon-Barrera KL, Mendoza-Martinez VM, Sanchez Medina GA, Leon-Hernandez M, Ruiz-Barranco A, Escobedo G, Melendez G. Chronic sucralose consumption induces elevation of serum insulin in young healthy adults: a randomized, double blind, controlled trial. Nutr J. 2020 Apr 13;19(1):32. doi: 10.1186/s12937-020-00549-5.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2635.2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gut Microbiota
-
Shanghai 10th People's HospitalRecruitingGut MicrobiotaChina
-
University of California, DavisCompletedGut MicrobiotaUnited States
-
TCI Co., Ltd.Completed
-
University of AberdeenNHS GrampianRecruitingGut MicrobiotaUnited Kingdom
-
University of ReadingCompleted
-
Biofortis, Merieux NutriSciencesLonza Inc.CompletedGut MicrobiotaUnited States
-
Kosin University Gospel HospitalCompleted
-
University of California, BerkeleyCompleted
-
Pennington Biomedical Research CenterWithdrawnGut Microbiota
-
University Hospital, Clermont-FerrandNeuromed IRCCS; Centre de Recherche en Nutrition Humaine d'Auvergne; Mediterranean...Unknown
Clinical Trials on sucralose
-
Yale UniversityCompletedInsulin Resistance | Impairment of Oral PerceptionUnited States
-
Yale UniversityTerminatedObesity | Insulin ResistanceUnited States
-
University of ManitobaCompletedImpaired Glucose ToleranceCanada
-
Yale UniversityCompletedImpairment of Oral PerceptionUnited States
-
RenJi HospitalXinhua Hospital, Shanghai Jiao Tong University School of Medicine; ShiBei Hospital... and other collaboratorsUnknownDiabetes Mellitus, Type 2China
-
University of Illinois at Urbana-ChampaignNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Unilever R&DLeiden University Medical CenterCompleted
-
University Hospital, Basel, SwitzerlandCompletedGastrointestinal Hormones | Glycemic Control | Appetite | Satiation | Reward Responses | Emotional StateSwitzerland
-
University of AarhusCompleted
-
University Hospital, Basel, SwitzerlandCompletedGastrointestinal Hormones | Energy Intake | Glycemic Control | Appetite | SatiationSwitzerland